CEBINA publishes data demonstrating the anti-histamine azelastine inhibits infection by major variants of SARS-CoV-2

CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announces the publication of research results demonstrating that the commonly used

Related Keywords

Austria ,Vienna ,Wien ,Sophie Zettl ,Eszter Nagy ,Robert Konrat ,Healthcare Pharmaceuticals Industry ,University Of Vienna ,Central European Biotech Incubator ,Professor Dr Robert Konrat ,Anti Histamine Azelastine ,Computational Drug Repurposing ,Inhibits Infection ,Major Variants ,Cell Cultures ,Reconstituted Human Tissue ,Internet News Presswire ,Editorial Guidelines ,Cebina ,Publishes ,Data ,Demonstrating ,The ,Anti Histamine ,Azelastine ,Inhibits ,Infection ,Baby ,Major ,Variants ,Of ,Sars Cov 2 ,